{"denoms":[{"counts":[{"groupId":"BG000","value":"11"}],"units":"Participants"}],"groups":[{"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nCarmustine: 300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.\n\nCytarabine: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nEtoposide: VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nMelphalan: 140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.\n\nPeripheral Blood Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"BG000","title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.4","value":"61"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.7","value":"51"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.9","value":"61"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Patients per arm were displayed.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients per arm were displayed.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients per arm were displayed.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients per arm were displayed.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"}],"units":"Participants"}],"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients per arm were displayed.","title":"Bone Marrow Biopsy status","unitOfMeasure":"Participants"}],"populationDescription":"Participants received Stem Cell Gene Therapy"}